BHC · Bausch Health Companies Inc.
$6.44
-0.77% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$22B
Trailing P/E
—
Forward P/E
1.5
Dividend yield
0.0%
Beta
0.37
Avg volume
3M
Employees
20K
Daily Change %
-0.77%
5 Days Change
3.02%
10 Days Change
10.19%
30 Days Change
13.66%
60 Days Change
-2.84%
Month to Day Change
13.26%
Year to Day Change
-6.62%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BHC
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-27
Latest call per bank · past 12 months
RBC Capital
Sector Perform$9.00
+39.8% vs priceBarclays
Equal-Weight$7.00
+8.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-27 | RBC Capital | Maintains | Sector Perform | $10.00 → $9.00 |
| 2026-02-25 | Barclays | Maintains | Equal-Weight | $8.00 → $7.00 |
| 2026-01-07 | Truist Securities | Maintains | Hold | $7.00 → $8.00 |
| 2025-12-09 | Barclays | Initiates | Equal-Weight | $0.00 → $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 64 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 4.2% above the 50-day MA ($6.18).
- bullish: Price vs 200-day MA: Trading 13.0% above the 200-day MA ($5.70).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.06) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($4.43) and high ($7.90).
BHC Price Chart
Loading chart for BHC…
Fundamentals
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 30.6% YTD
TEVA
Teva Pharmaceutical Industries
$46B 28.8% YTD
HLN
Haleon plc
$45B 4.6% YTD
ZTS
Zoetis Inc.
$33B -33.8% YTD
UTHR
United Therapeutics Corporation
$25B 20.0% YTD
VTRS
Viatris Inc.
$21B 51.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 1.0% YTD
ELAN
Elanco Animal Health Incorporat
$11B 0.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.